Literature DB >> 2313793

Decreased urinary uronic acid levels in individuals with interstitial cystitis.

C L Parsons1, R E Hurst.   

Abstract

The pathogenesis of interstitial cystitis currently is unknown. A possible etiology is that the transitional epithelium is defective, leading to molecular leaks that initiate the disease complex. An important surface defense mechanism is the glycosaminoglycans or polysaccharides that line the bladder epithelium and act as a nonspecific antiadherence factor blocking access of bacteria, microcrystals, proteins and ions to the underlying transitional cells. We examined the excretion of urinary macromolecular uronic acid and glycosaminoglycans in normal individuals and those with interstitial cystitis. A total of 37 controls had a mean macromolecular uronic acid level of 56 nmol. per mg. creatinine, compared to 40.2 nmol. per mg. creatinine in 43 patients with active disease (differences were significant, p equals 0.03). The median excretions of glycosaminoglycan uronate for controls and patients were 15.1 and 11.1 nmol. per mg. creatinine, respectively. (There was an over-all tendency to decrease excretion in patients with a p value of 0.06.) Specimens obtained at cystoscopy from patients with active interstitial cystitis had ureteral macromolecular uronic acid levels of 40.5 nmol. uronate per mg. creatinine compared to 43.6 nmol. uronate per mg. creatinine from the bladder. Interstitial cystitis patients had 16.0 nmol. glycosaminoglycan uronate per mg. creatinine compared to 14.6 nmol. per mg. creatinine in normal controls. Neither of these differences was statistically significant. It would appear that there is a tendency to lower macromolecular uronic acid and polysaccharide excretion in individuals afflicted with this syndrome.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2313793     DOI: 10.1016/s0022-5347(17)40061-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

Review 1.  Interstitial cystitis.

Authors:  D R Erickson; M F Davies
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1998

2.  Abnormalities in Expression of Structural, Barrier and Differentiation Related Proteins, and Chondroitin Sulfate in Feline and Human Interstitial Cystitis.

Authors:  Paul J Hauser; Samuel B VanGordon; Jonathan Seavey; Troy M Sofinowski; Mohammad Ramadan; Shivon Abdullah; C A Tony Buffington; Robert E Hurst
Journal:  J Urol       Date:  2015-01-28       Impact factor: 7.450

3.  Long-term ketamine abuse induces cystitis in rats by impairing the bladder epithelial barrier.

Authors:  Di Gu; Jun Huang; Youle Yin; Zhengfei Shan; Shaobin Zheng; Peng Wu
Journal:  Mol Biol Rep       Date:  2014-08-05       Impact factor: 2.316

4.  Decreased urinary glycosaminoglycan excretion following alfuzosin treatment on ureteral stent-related symptoms: a prospective, randomized, placebo-controlled study.

Authors:  Shucheng Liu; Ying Yu; Yang Gao; Xiong Yang; Zili Pang
Journal:  Urolithiasis       Date:  2015-08-05       Impact factor: 3.436

5.  Pretreatment features to influence effectiveness of intravesical hyaluronic Acid instillation in refractory interstitial cystitis/painful bladder syndrome.

Authors:  Aram Kim; Bumjin Lim; Miho Song; Myung-Soo Choo
Journal:  Int Neurourol J       Date:  2014-09-24       Impact factor: 2.835

Review 6.  The role(s) of cytokines/chemokines in urinary bladder inflammation and dysfunction.

Authors:  Eric J Gonzalez; Lauren Arms; Margaret A Vizzard
Journal:  Biomed Res Int       Date:  2014-03-12       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.